ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Disease stage-specific atrophy markers in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Multimodal MRI insights into hippocampal pathological changes across the Alzheimer's disease continuum: advances and challenges.Japanese journal of radiology · 2026Review
- A longitudinal analysis of T1-weighted MRI features associated with progression from mild cognitive impairment to Alzheimer's disease.BMC medical imaging · 2026Article
- Dysfunction of the episodic memory network in the Alzheimer's disease cascade.Nature communications · 2026Article
- Contribution of Life-Course Socioeconomic Position to Later-Life Brain Volumes in US Hispanic/Latino Adults.Neurology · 2026Article
- Abnormal signal transmission in white matter revealed by resting-state communication connectivity in Alzheimer's disease: A comprehensive cross-sectional and longitudinal study.Translational psychiatry · 2026Article
- Integrating standard and native spaces for radiomics and brain network analysis in Alzheimer's disease diagnosis and prognosis.Journal of neurology · 2026Article
- Disease stage-specific atrophy markers in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comparison of microglial cell population expansion in theJournal of Alzheimer's disease reportsArticle
- Beneficial effects of foreign language learning and aerobic exercise on dentate gyrus volume and mnemonic discrimination in healthy older adults: Results from a randomized controlled trial.Imaging neuroscience (Cambridge, Mass.)Article
- Deep learning-based cortical thickness maps for diagnosis of neurodegenerative diseases: a rater study.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Update of
Authors and funding
52 authors.
Funding
Abstract
introductionStructural magnetic resonance imaging (MRI) often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal atrophy markers for different intended uses.
methodsWe included 363 older adults; cognitively unimpaired individuals who were negative or positive for amyloid beta (Aβ) and Aβ-positive patients with subjective cognitive decline, mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to 3 years.
resultsAccelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Atrophy-cognition relationships varied by intended use and disease stage. DISCUSSION: With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use. HIGHLIGHTS: Subregional atrophy markers detect ongoing atrophy in preclinical Alzheimer's disease (AD). Subjective cognitive decline in preclinical AD links to manifest atrophy. Optimal atrophy markers differ by the disease stage and intended use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.